These improvements are likely because the monoclonal antibody is capable of binding specifically to HER-2 and blocking its dimerization, interfering with its signaling for increased proliferation, while conjugated emtansine further propagates the anti-cancer effect by triggering apoptosis via mitotic arrest [8]. The gene discussed is ERBB2; the disease is cancer.